These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

564 related items for PubMed ID: 28365054

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. A new dawn for managing dyslipidemias: The era of rna-based therapies.
    Macchi C, Sirtori CR, Corsini A, Santos RD, Watts GF, Ruscica M.
    Pharmacol Res; 2019 Dec; 150():104413. PubMed ID: 31449975
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Emerging drugs for hyperlipidemia.
    Paras C, Hussain MM, Rosenson RS.
    Expert Opin Emerg Drugs; 2010 Sep; 15(3):433-51. PubMed ID: 20423271
    [Abstract] [Full Text] [Related]

  • 28. Lipid-Modifying Drugs: Pharmacology and Perspectives.
    Xu RX, Wu YJ.
    Adv Exp Med Biol; 2020 Sep; 1177():133-148. PubMed ID: 32246446
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Suboptimal lipid levels in clinical practice among Portuguese adults with dyslipidemia under lipid-lowering therapy: Data from the DISGEN-LIPID study.
    da Silva PM, Aguiar C, Morais J, DISGEN-LIPID study Investigators.
    Rev Port Cardiol (Engl Ed); 2019 Aug; 38(8):559-569. PubMed ID: 31706732
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Ongoing challenges for pharmacotherapy for dyslipidemia.
    Pisaniello AD, Scherer DJ, Kataoka Y, Nicholls SJ.
    Expert Opin Pharmacother; 2015 Feb; 16(3):347-56. PubMed ID: 25476544
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs.
    Kones R, Rumana U.
    Drugs; 2015 Jul; 75(11):1201-28. PubMed ID: 26169307
    [Abstract] [Full Text] [Related]

  • 36. Novel Hypolipidaemic Drugs: Mechanisms of Action and Main Metabolic Effects.
    Filippatos TD, Liontos A, Christopoulou EC, Elisaf MS.
    Curr Vasc Pharmacol; 2019 Jul; 17(4):332-340. PubMed ID: 29424317
    [Abstract] [Full Text] [Related]

  • 37. Novel molecules targeting dyslipidemia and atherosclerosis.
    Tavridou A, Manolopoulos VG.
    Curr Med Chem; 2008 Jul; 15(8):792-802. PubMed ID: 18393849
    [Abstract] [Full Text] [Related]

  • 38. Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion.
    Kappelle PJ, van Tol A, Wolffenbuttel BH, Dullaart RP.
    Cardiovasc Ther; 2011 Dec; 29(6):e89-99. PubMed ID: 20645987
    [Abstract] [Full Text] [Related]

  • 39. [Diabetic dyslipidaemia and the atherosclerosis].
    Márk L, Dani G.
    Orv Hetil; 2016 May 08; 157(19):746-52. PubMed ID: 27133274
    [Abstract] [Full Text] [Related]

  • 40. Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study.
    Halcox JP, Banegas JR, Roy C, Dallongeville J, De Backer G, Guallar E, Perk J, Hajage D, Henriksson KM, Borghi C.
    BMC Cardiovasc Disord; 2017 Jun 17; 17(1):160. PubMed ID: 28623902
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 29.